… Thus, potent, broadly-acting oral antivirals targeting the CoV family are needed to treat those
at high risk for severe COVID-19 as well as future emerging CoV infections. For an antiviral …

… COVID-19. To benefit individual and public health, clinical applications of molnupiravir to
promptly treat COVID-19 … We believe that early molnupiravir treatment in asymptomatic or mildly …

… avenue for COVID-19 treatment. Recently, molnupiravir is a prodrug antiviral medication
that was approved in the United Kingdom in November 2021 for the treatment of COVID-19. On …

… The present study describes the favorable evolution of a series of KTRs with COVID-19
treated with molnupiravir compared with a cohort of patients receiving remdesivir. …

… The most severe symptoms of COVID-19 (fever, muscle and joint … treatment with molnupiravir
in all the patients from the group not requiring admission to the hospital due to COVID-19 (ie…

… Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral
treatments, … The aim of this ongoing platform trial is to compare different antiviral treatments …

… molnupiravir reduced the risk of admission to hospital or death by around 50% in non-hospitalised
adults who had mild to moderate covid-19 … molnupiravir group discontinued treatment …

… period were defined as having treatment exposure. Because all public … COVID-19 as clinically
appropriate on the basis of the same set of standard treatment protocols, and molnupiravir …

… Our results also showed a larger magnitude of risk reduction with molnupiravir treatment
in older people than in younger people. Our findings provide evidence for the use of …

… Indeed, for vulnerable groups and patients with severe or critical severe COVID-19, we …
mortality with molnupiravir treatment.We share your concerns about the efficacy of molnupiravir, …